Jonathan Chang
Stock Analyst at Leerink Partners
(3.93)
# 1,820
Out of 4,455 analysts
552
Total ratings
36.6%
Success rate
6.3%
Average return
Main Sectors:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Reiterated: Hold | n/a | $11.63 | - | 49 | Jun 2, 2026 | |
| MOLN Molecular Partners AG | Reiterated: Buy | n/a | $3.80 | - | 7 | Jun 2, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $67 → $147 | $182.08 | -19.27% | 40 | Apr 13, 2026 | |
| NBTX Nanobiotix | Maintained: Buy | $24 → $37 | $35.99 | +2.81% | 17 | Apr 1, 2026 | |
| IMTX Immatics | Reiterated: Buy | $17 | $9.53 | +78.38% | 44 | Mar 6, 2026 | |
| AKTS Aktis Oncology | Initiated Coverage: Buy | $31 | $29.44 | +5.30% | 1 | Feb 3, 2026 | |
| NVCR NovoCure | Reiterated: Buy | $33 → $24 | $15.43 | +55.54% | 19 | Jan 13, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $20 | $10.90 | +83.49% | 51 | Jan 13, 2026 | |
| ZLAB Zai Lab | Reiterated: Buy | $74 | $18.00 | +311.11% | 51 | Oct 21, 2025 | |
| GMAB Genmab | Reiterated: Buy | $34 → $39 | $26.12 | +49.31% | 45 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 → $6 | $10.21 | -41.23% | 36 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 → $5 | $4.81 | +3.95% | 38 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $0.11 → $0.09 | $0.0389 | +131.36% | 38 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $4.10 | +485.37% | 30 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $30.88 | +94.30% | 13 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $27 | $15.05 | +79.40% | 32 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.0127 | n/a | 23 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $887.18 | n/a | 1 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $53.90 | n/a | 1 | Jan 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $18 → $2 | $0.0004 | n/a | 15 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.01 | n/a | 1 | Jun 1, 2022 |
Replimune Group
Jun 2, 2026
Reiterated: Hold
Price Target: n/a
Current: $11.63
Upside: -
Molecular Partners AG
Jun 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.80
Upside: -
Revolution Medicines
Apr 13, 2026
Reiterated: Buy
Price Target: $67 → $147
Current: $182.08
Upside: -19.27%
Nanobiotix
Apr 1, 2026
Maintained: Buy
Price Target: $24 → $37
Current: $35.99
Upside: +2.81%
Immatics
Mar 6, 2026
Reiterated: Buy
Price Target: $17
Current: $9.53
Upside: +78.38%
Aktis Oncology
Feb 3, 2026
Initiated Coverage: Buy
Price Target: $31
Current: $29.44
Upside: +5.30%
NovoCure
Jan 13, 2026
Reiterated: Buy
Price Target: $33 → $24
Current: $15.43
Upside: +55.54%
Kura Oncology
Jan 13, 2026
Reiterated: Buy
Price Target: $20
Current: $10.90
Upside: +83.49%
Zai Lab
Oct 21, 2025
Reiterated: Buy
Price Target: $74
Current: $18.00
Upside: +311.11%
Genmab
Oct 13, 2025
Reiterated: Buy
Price Target: $34 → $39
Current: $26.12
Upside: +49.31%
Oct 10, 2025
Maintained: Hold
Price Target: $8 → $6
Current: $10.21
Upside: -41.23%
Aug 18, 2025
Maintained: Buy
Price Target: $8 → $5
Current: $4.81
Upside: +3.95%
Aug 13, 2025
Maintained: Hold
Price Target: $0.11 → $0.09
Current: $0.0389
Upside: +131.36%
Aug 11, 2025
Reiterated: Buy
Price Target: $24
Current: $4.10
Upside: +485.37%
Aug 11, 2025
Maintained: Buy
Price Target: $60
Current: $30.88
Upside: +94.30%
Aug 7, 2025
Reiterated: Buy
Price Target: $27
Current: $15.05
Upside: +79.40%
Nov 12, 2024
Reiterated: Buy
Price Target: $2
Current: $0.0127
Upside: n/a
Jun 30, 2023
Maintained: Buy
Price Target: n/a
Current: $887.18
Upside: n/a
Jan 11, 2023
Rated: Buy
Price Target: n/a
Current: $53.90
Upside: n/a
Nov 14, 2022
Downgraded: Hold
Price Target: $18 → $2
Current: $0.0004
Upside: n/a
Jun 1, 2022
Maintained: Buy
Price Target: n/a
Current: $4.01
Upside: n/a